Current concepts in malignant pleural mesothelioma

Expert Review of Anticancer Therapy

Volumn 8, Issue 2, 2008, Pages 293-303

  Kaufman, Andrew J ^a   Pass, Harvey I ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Malignant pleural mesothelioma; Multimodality therapy; Radiotherapy; Surgery

Indexed keywords

ASBESTOS; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DOXORUBICIN; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; IMATINIB; MESOMARK; MESOTHELIN; MITOMYCIN C; NAVELBINE; PEMETREXED; RALTITREXED; RANPIRNASE; THALIDOMIDE; UNCLASSIFIED DRUG; VATALANIB; VINBLASTINE;

ADJUVANT THERAPY; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC SUSCEPTIBILITY; HUMAN; INCIDENCE; LABORATORY TEST; LUNG RESECTION; MONOTHERAPY; NONHUMAN; OCCUPATIONAL CARCINOGENESIS; OCCUPATIONAL EXPOSURE; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PLEURECTOMY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SEX DIFFERENCE; SIMIAN VIRUS 40; SURVIVAL RATE; SURVIVAL TIME; THORACOSCOPY; THORAX PAIN; THORAX RADIOGRAPHY; VIRUS INFECTION;

CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MESOTHELIOMA; NEOPLASM STAGING; PLEURAL NEOPLASMS; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL ANALYSIS; THORACIC SURGICAL PROCEDURES; TREATMENT OUTCOME;

EID: 40749158168     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.2.293     Document Type: Article

References (118)

1. Ismail-Khan R, Robinson LA, Williams CC Jr et al. Malignant pleural mesothelioma: a comprehensive review. Cancer Control 13(4), 255-263 (2006).
2. Kazan-Allen L. Asbestos and mesothelioma: worldwide trends. Lung Cancer 49(Suppl. 1), S3-S8 (2005).
3. Tsiouris A, Walesby RK. Malignant pleural mesothelioma: current concepts in treatment. Nat. Clin. Pract, Oncol. 4(6), 344-352 (2007).
4. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 366(9483), 397-408 (2005).
5. Carbone M, Albelda SM, Broaddus VC et al. Eighth International Mesothelioma Interest Group. Oncogene 26(49), 6959-6967 (2007).
6. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest. 14(5), 466-480 (1996).
7. Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann. NY Acad. Sci. 643, 182-193 (1991).
8. Hodgson JT McElvenny DM, Darnton AJ, Price MJ, Peto J. The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br. J. Cancer 92(3), 587-593 (2005).
9. Peto J, Decarli A, La Vecchia C, Levi F, Negri E. The European mesothelioma epidemic. Br. J. Cancer 79(3,4), 666-672 (1999).
10. Pass HI, Vogelzang; NJ, Hahn SM, Carbone M. Cancer Principles & Williams Practice of Oncology (7th Edition). Pass HI, Vogelzang N, Carbone M (Eds). Lippincot and Wilkins, PA, USA 1687-1715 (2005).
11. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br. J. Ind Med. 17, 260-271 (1960).
12. Yang H, Pass HI, Carbone M. Pathogenesis, of mesothelioma. In: Mesothelioma from Bench to Clinic. Baldi A (Ed.). Nova Science Publishers, NY, USA (In Press).
13. Musk AW, de Klerk NH, Eccles JL et al. Wittenoom, Western Australia: a modern industrial disaster. Am. J. Ind. Med. 21(5), 735-747 (1992).
14. McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer 46(7), 1650-1656 (1980).
15. Smith AH, Wright CC. Chrysotile asbestos is the main cause of pleural mesothelioma. Am. J. Ind. Med. 30(3), 252-266 (1996).
16. Baris I, Simonato L, Artvinli M et al. Epidemiological and environmental evidence of the health effects of exposure to erionite fibres: a four-year study in the Cappadocian region of Turkey. Int. J. Cancer 39(1), 10-17 (1987).
17. Baris YI, Artvinli M, Sahin AA. Environmental mesothelioma in Turkey. Ann. AY Acad. Sci. 330, 423-432 (1979).
18. Carbone M, Emri S, Dogan AU et al. A mesothelioma epidemic in Cappadocia: scientific developments and unexpected social outcomes. Nat. Rev. Cancer 7(2), 147-154 (2007).
19. Dogan AU, Baris YI, Dogan M et al. Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey. Cancer Res. 66(10), 5063-5068 (2006).
20. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M. Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet 357(9254), 444-445 (2001).
21. Kamp DW, Israbian VA, Preusen SE, Zhang CX, Weitzman SA. Asbestos causes DNA strand breaks in cultured pulmonary epithelial cells: role of iron-catalyzed free radicals. Am. J. Physiol. 268(3 Pt 1), L471-L480 (1995).
22. Shukla A, Gulumian M, Hei TK et al. Multiple roles of oxidants in the pathogenesis of asbestos-induced diseases. Free Radic. Biol. Med. 34(9), 1117-1129 (2003).
23. Xu A, Zhou H, Yu DZ, Hei TK. Mechanisms of the genotoxicity of crocidolite asbestos in mammalian cells: implication from mutation patterns induced by reactive oxygen species. Environ. Health Perspect. 110(10), 1003-1008 (2002).
24. Bell DW, Jhanwar SC, Testa JR. Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. Cancer Res. 57(18), 4057-4062 (1997).
25. Lee WC, Balsara B, Liu Z. Jhanwar SC, Testa JR. Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. Cancer Res. 56(19), 4297-4301 (1996).
26. Taguchi T, Jhanwar SC, Siegfried JM, Keller SM, Testa JR. Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. Cancer Res. 53(18), 4349-4355 (1993).
27. Bianchi, AB, Mitsunaga SI, Cheng JQ et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc. Natl Acad. Sci. USA 92(24), 10854-10858 (1995).
28. Cheng JQ, Jhanwar SC, Klein WM et al. p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res. 54(21), 5547-5551 (1994).
29. Krismann M, Muller KM, Jaworska M, Johnen G. Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases. J. Pathol. 197(3), 363-371 (2002).
30. Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma (review). Int J. Oncol. 14(1), 181-188 (1999).
31. Metcalf RA, Welsh JA, Bennett WP et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res. 52(9), 2610-2615 (1992).
32. Sekido Y, Pass HI. Bader S et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res. 55(6), 1227-1231 (1995).
33. Altomare DA.You H, Xiao GH et al. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene 24(40), 6080-6089 (2005).
34. Kumar-Singh S, Segers K, Rodeck U et al. WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis. J. Pathol. 181(1), 67-74 (1997).
35. Bocchetta M, Di Resta I, Powers A et al. Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity. Proc. Natl. Acad. Sci. USA 97(18), 10214-10219 (2000).
36. Lechner JF, Tokiwa T, LaVeck M et al. Asbestos-associated chromosomal changes in human mesothelial cells. Proc. Natl Acad. Sci. USA 82(11), 3884-3888 (1985).
37. Yang H, Bocchetta M, Kroczynska B et al. TNF-α inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc. Natl Acad. Sci. USA 103(27), 10397-10402 (2006).
38. Choe N, Tanaka S, Xia W et al. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ. Health Perspect. 105(Suppl. 5), 1257-1260 (1997).
39. Gerwin BI, Lechner JF, Reddel RR et al. Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. Cancer Res. 47(23), 6180-6184 (1987).
40. Versnel MA, Hagemeijer A, Bouts MJ, van der Kwast TH, Hoogsteden HC. Expression of c-sis (PDGF B-chain) and PDGF A-chain genes in ten human malignant mesothelioma cell lines derived from primary and metastatic tumors. Oncogene 2(6), 601-605 (1988).
41. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ. Interleukin 6 induces the expression of vascular endothelial growth factor. J. Biol. Chem. 271(2), 736-741 (1996).
42. Galffy G, Mohammed KA, Dowling PA et al. Interleukin 8: an autocrine growth factor for malignant mesothelioma. Cancer Res. 59(2), 367-371 (1999).
43. Salgado R, Vermeulen PB, Benoy I et al. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients. Br. J. Cancer 80(5-6), 892-897 (1999).
44. Ramos-Nino ME, Timblin CR, Mossman BT. Mesothelial cell transformation requires increased AP-1 binding activity and ERK-dependent Fra-1 expression. Cancer Res. 62(21), 6065-6069 (2002).
45. Batra S, Shi Y, Kuchenbecker KM et al. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem. Biophys. Res. Commun. 342(4), 1228-1232 (2006).
46. Uematsu K, Kanazawa S, You L et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 63(15), 4547-4551 (2003).
47. Cutrone R, Lednicky J, Dunn G et al. Some oral poliovirus vaccines were contaminated with infectious SV40 after 1961. Cancer Res. 65(22), 10273-10279 (2005).
48. Carbone M, Kratzke RA, Testa JR. The pathogenesis of mesothelioma. Semin. Oncol. 29(1), 2-17 (2002).
49. Gazdar AF, Butel JS, Carbone M. SV40 and human tumours: myth, association or causality? Nat. Rev. Cancer 2(12), 957-964 (2002).
50. Wong M, Pagano JS, Schiller JT et al. New associations of human papillomavirus, Simian virus 40, and Epstein-Barr virus with human cancer. J. Natl Cancer Inst. 94(24), 1832-1836 (2002).
51. Lopez-Rios F, Illei PB, Rusch V, Ladanyi M. Evidence against a role for SV40 infection in human mesotheliomas and high risk of false-positive PCR results owing to presence of SV40 sequences in common laboratory plasmids. Lancet 364(9440), 1157-1166 (2004).
52. Comar M, Rizzardi C, de Zotti R et al. SV40 multiple tissue infection and asbestos exposure in a hyperendemic area for malignant mesothelioma. Cancer Res. 67(18), 8456-8459 (2007).
53. Kroczynska B, Cutrone R, Bocchetta M et al. Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters. Proc. Natl Acad. Sci. USA 103(38), 14128-14133 (2006).
54. Robinson C, van Bruggen I. Segal A et al. A novel SV40 TAg transgcnic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 66(22), 10786-10794 (2006).
55. Pietruska JR, Kane AB. SV40 oncoproteins enhance asbestos-induced DNA doublestrand breaks and abrogate senescence in murine mesothelial cells. Cancer Res. 67(8), 3637-3645 (2007).
56. Dahl IM, Solheim OP, Erikstein B, Muller E. A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease. Cancer 64(1), 68-73 (1989).
57. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362(9396), 1612-1616 (2003).
58. Beyer HL, Geschwindt RD, Glover CL et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin. Chem. 53(4),666-672 (2007).
59. Scherpereel A, Grigoriu. B, Conti M et al. Soluble mesothetin-related peptides in the diagnosis of malignant pleural mesothelioma. Am. J. Respir. Crit. Care Med. 173(10), 1155-1160 (2006).
60. Creancy J, Robinson BW. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol. Oncol. Clin. North Am. 19(6), 1025-1040, v (2005).
61. Cristaudo A, Foddis R, Vivaldi A et al. Clinical significance ofserun mesothelin in patients with mesothelioma and lung cancer. Clin. Cancer Res. 13(17), 5076-5081 (2007).
62. Grigoriu BD, Scherpereel A, Devos P et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin. Cancer Res. 13(10), 2928-2935(2007).
63. Pass HI, Lott D, Lonardo F et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N. Engl, J. Med. 353(15), 1564-1573 (2005).
64. Pass HI, Liu Z, Wali A et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 10(3), 849-859 (2004).
65. Sandhu H, Dehnen W, Roller M, Abel J, Unfried K. mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. Carrinogenesis 21(5), 1023-1029 (2000).
66. Rusch VW, Godwin JD, Shuman WP. The role of computed tomography scanning in the initial assessment and the follow-up of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 96(1), 171-177 (1988).
67. Patz EF Jr, Shaffer K, Piwnica-Worms DR et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR Am J. Roentgenol. 159(5), 961-966 (1992).
68. Pass HI, Terneck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J. Thorac. Candiovasc. Surg. 115(2), 310-317; discussion 317-318 (1998).
69. Flores RM. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 49(Suppl. 1), S27-S32 (2005).
70. Benard F, Sterman D, Smith RJ et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 114(3), 713-722 (1998).
71. Flores RM, Akhurst T, Gonen M, Larson SM, Rusch VW. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 126(1), 11-16 (2003).
72. Flores RM, Akhurst T, Gonen M et al. Positron emission tomography predicts survival in malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 132(4), 763-768 (2006).
73. Erasmus JJ, Truong MT, Smythe WR et al. Integrated computed tomography-positron emission tomography in patients with potentially resbetable malignant pleural mesothelioma: staging implications. J. Thorac. Cardiovasc. Surg. 129(6), 1364-1370 (2005).
74. Nowak AK. CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 49(Suppl. 1), S37-S40 (2005).
75. 18F]fluorodeoxyglucose. J. Clin. Oncol. 24(28), 4587-4593 (2006).
76. Flores RM RV. Diffuse Malignant Mesothelioma. Shields TW, Locicero J, Ponn RB, Rusch VW (Eds). Lippincott Williams & Wilkins, NY, USA (2005).
77. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 1: diagnosis. Cancer 72(2), 389-393 (1993).
78. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108(4), 1122-1128 (1995).
79. Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer expcrience. J. Clin. Oncol. 16(1), 145-152 (1998).
80. Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 113(3), 723-731 (1998).
81. Ruffie P, Feld R, Minkin S et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J. Clin. Oncol. 7(8), 1157-1168 (1989).
82. Gordon GJ, Rockwell GN, Godfrey PA et al. Validation of genomics-based prognostic tests in malignant pleural mesothelioma. Clin. Cancer Res. 11(12), 4406-4414 (2005).
83. Lopez-Rios F, Chuai S, Flores R et al. Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation Of microarray-based prognostic prediction. Cancer Res. 66(6), 2970-2979 (2006).
84. Pilling JE, Stewart DJ, Martin-Ucar AE et al. The case for routine cervical mediastinoscopy prior to radical surgery for malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 25(4), 497-501 (2004).
85. Maziak DE, Gagliardi A, Haynes AE, Mackay JA, Evans WK. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 48(2), 157-169 (2005).
86. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21(14), 2636-2644 (2003).
87. Flores RM, Pass H, Venkatraman E et al. Extrapleural pnuemonectomy (EPP) versus pleurectomy/decortication (PD) in the surgical management of malignant pleural mesothelioma (MPM): results in 663 patients. In: The American Association for Thoracic Surgery 87th Annual Meeting. Washington, DC, USA, 5-9 May 2007.
88. Rusch VW, Piantadosi S, Holmes EC. The role of extraplearal pneunionectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J. Thorac. Cardiovasc. Surg. 102(1), 1-9 (1991).
89. Aziz T, Jilaihawi A, Prakash D. The management of malignant pleural mesothelioma; single centre experience in 10 years. Eur. J. Cardiothorac. Surg. 22(2), 298-305 (2002).
90. Achatzy R, Beba W, Ritschler R et al. The diagnosis, therapy and prognosis of diffuse malignant mesothelioma. Eur. J. Cardiothorac. Surg. 3(5), 445-447; discussion 448 (1989).
91. Brancatisano RP, Joseph MG, McCaughan BC. Pleurectomy for mesothelioma. Med. J. Aust. 154(7), 455-457, 460 (1991).
92. Soysal O, Karaoglanoglu N, Demiracan S et al. Pleurectomy/ decortication for palliation in malignant pleural mesothelioma: results of surgery. Eur. J. Cardiothorac. Surg. 11(2), 210-213 (1997).
93. Rusch V, Saltz L, Venkatraman E et al. A Phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J. Clin. Oncol. 12(6), 1156-1163 (1994).
94. Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van der Merwe CA. Malignant pleural mesothelioma: a disease unaffected by current therapeutic maneuvers. J. Clin. Oncol. 6(3), 527-535 (1988).
95. Holsti LR, Pyrhonen S, Kajanti M et al. Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment. Acta Oncol. 36(4), 397-405 (1997).
96. Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M. Malignant mesothelioma of the pleura. a study of 52 treated and 64 untreated patients. Thorax 39(4), 255-259 (1984).
97. Berghmans T, Paesmans M, Lalami Y et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2), 111-121 (2002).
98. Broomfield S, Currie A, van der Most RG et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 65(17), 7580-7584 (2005).
99. Steele JP, Shamash J, Evans MT et al. Phase-II study of vinorelbine in patients with malignant pleural mesothelioma. J. Clin. Oncol. 18(23), 3912-3917 (2000).
100. Mintzer DM, Kelsen D, Frimmer D, Heelan R, Gralla R. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat. Rep. 69(6), 711-712 (1985).
101. van Meerbeeck JP. Gaafar R, Manegold C et al. Randomized Phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation fbr Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J. Clin. Oncol. 23(28), 6881-6889 (2005).
102. Ceresoli GL, Zucali PA, Favazetto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J. Clin. Oncol. 24(9), 1443-1448 (2006).
103. Costanzi J, Sidransky D, Navon A, Goldsweig H. Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest. 23(7), 643-650 (2005).
104. Sugarbakcr DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 117(1), 54-63; discussion 63-55 (1999).
105. Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 68(5), 1799-1804 (1999).
106. de Perrot M, Uy K, Anraku M et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 133(1), 111-116 (2007).
107. Rusch VW, Rosenzweig K, Venkatraman E et al. A Phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 122(4), 788-795 (2001).
108. Allen AM, Czerminska M, Janne PA et al. Fatal pneumonitis associated with intensity-modulated radiation therpy for mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 65(3), 640-645 (2006).
109. Weder W, Kestenholz P, Tavern C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 22(17), 3451-3457 (2004).
110. Flores RM, Krug LM, Rosenzweig KE et al. Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a Phase II trial. J. Thorac. Oncol. 1(4), 289-295 (2006).
111. Weder W, Stahel R, Bernhard J et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 18(7), 1196-1202 (2007).
112. Krug L, Pass H, Rusch VW et al. A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM). J. Clin. Oncol. 25(Suppl. 18), 7561 (2007).
113. Garland LL, Rankin C, Gandara DR et al. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J. Clin. Oncol. 25(17), 2406-2413 (2007).
114. Govindan R, Kratzke RA. Hemdon JE II et al. Gefitinib in patients with malignant mesothelioma: a Phase II study by the Cancer and Leukemia Group B. Clin. Cancer Res. 11 (6), 2300-2304 (2005).
115. Mathy A, Baas P. Dalesio O, van Zandwijk N. Limited efficacy of imatinib mesylate in malignant mesothelioma: a Phase II trial. Lung Cancer 50(1), 83-86 (2005).
116. Karrison T, Kindler HL, Gandara DR et al. Final Analysis of a multi-center, double-blind, placebo-controlled, randomized Phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with maligmant mesothlioma (MM). J. Clin. Oncol. 25(Suppl. 18), 7526 (2007).
117. Baas P, Boogerd W, Dalesio O et al. Thalidomide in patients with malignant pleural mesothelioma. Lung Cancer 48(2), 291-296 (2005).
118. Jahan T Gu L, Wang X et al. Vatalanib in patients with previously untreated advanced malignant mesothelioma (MM): Preliminary analysis of a Phase II study by the Cancer and Leukemia Group B (CALGB 30107). Lung Cancer 49(Suppl. 2), A222 (2005).